You are here

FDA Accepts IND for Optina (Danazol) for Treatment of Diabetic Macular Edema

Clinical trial expected in first quarter, 2013 (Jan. 22)

The planned multicenter trial will evaluate the safety and efficacy of 12 weeks of treatment with oral Optina compared with placebo in adult patients with DME. The patients will be randomized to receive one of two dosages of Optina (0.5 mg per BMI or 1.0 mg per BMI per day) or placebo. After the patients have completed 4 weeks of initial treatment, an interim analysis will determine the best dose of Optina. Following the 12-week active treatment period, there will be a further 4-week washout period. The primary endpoint is improvement in visual acuity, defined by responder status, compared with placebo. Following treatment and washout, the patients will be assessed for vision regression, and a 12-week open-label extension study will be offered to evaluate the duration of the effect of the optimal dose. A total of 450 patients are expected to enroll.

Optina is a drug based on a low dose of danazol mdash; a weak androgen, low-molecular-weight, lipophilic steroid. In vitro data suggest that danazol has a biphasic effect on endothelial cells: at low doses, the drug decreases vascular leakage, while at higher concentrations an increase in vascular permeability is observed.

Source: Ampio Pharmaceticals; January 22, 2013.

Recent Headlines

Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring
But a ‘Serendipitous’ Finding Could Provide a Solution
New Drug Could Make Ears “Young” Again
DNA Changes May Help Predict Women at Risk
Finding Could Spur New Targeted Treatments